Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ BATF Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5104545
Description
Antibody detects endogenous levels of total BATF.
BATF is a nuclear basic leucine zipper protein that belongs to the AP-1/ATF superfamily of transcription factors. The leucine zipper of this protein mediates dimerization with members of the Jun family of proteins. This protein is thought to be a negative regulator of AP-1/ATF transcriptional events and blocks cellular transformation by Ras and Fos. BATF also is required for the differentiation of IL-17-producing T helper (TH17) cells, a CD4+ subset of T cells that coordinates the inflammatory response in host defense. In both T cells and B cells, BATF is required for the appropriate regulation of the class-switch recombination.
Specifications
BATF | |
Polyclonal | |
Unconjugated | |
Batf | |
activating transcription factor B; basic leucine zipper ATF-like transcription factor; basic leucine zipper transcription factor, ATF-like; basic leucine zipper transcription factor-like; basic leucine zipper transcriptional factor ATF-like; BATF; B-ATF; BATF1; B-cell activating transcription factor; B-cell-activating transcription factor; SFA2; SFA-2; SF-HT-activated gene 2 protein; si:ch211-153j24.4 | |
Rabbit | |
Affinity chromatography | |
RUO | |
10538, 53314 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
O35284, Q16520 | |
Batf | |
A synthesized peptide derived from human BATF(Accession Q16520), corresponding to amino acid residues M1-K50. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction